Toronto Stock Exchange, TSX Venture ExchangeToronto, Ontario--(Newsfile Corp. - October 9, 2025) - TMX Group today announced its financing activity on Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) for September 2025.TSX welcomed 29 new issuers in September 2025, compared with 44 in the previous month and 13 in September 2024. The new listings were 27 exchange traded products, one mining company and one consumer products & services company. Total financings raised in September 2025 increased ...

XAI needs a way to finance all of the GPUs that are going to go into Colossus 2, its next big data center in Memphis, Tennessee. Here's how we've reported that they're going to do it. They've set up with investors a special purpose vehicle or SPV, basically a financing shell that buys Nvidia processors and then rents them back to XAI.Our understanding is the round's now up to around $20 billion split between $12.5% billion of debt and $7.5% billion in equity. Nvidia is putting around $2 billion into the equ ...

PesoRama Reports 2026 Q2 Financial ResultsSeptember 25, 2025 8:00 AM EDT | Source: PesoRama Inc.Total sales increased by 20% in 2025 compared to 2024 (i)Product gross margins increased by 3.2% to 46%Same store sales increased by 5% in 2025 compared to 2024 (i)Average ticket increased by 20.2% in 2025 compared to 2024Closed $6.8 million in oversubscribed equity financingToronto, Ontario--(Newsfile Corp. - September 25, 2025) - PesoRama Inc. (TSXV: PESO) ("PesoRama" or the "Company"), a Canadian ...

Lion One Announces Closing of Upsized LIFE Offering for Gross Proceeds of $18.7 MillionSeptember 24, 2025 7:25 PM EDT | Source: Lion One Metals LimitedNorth Vancouver, British Columbia--(Newsfile Corp. - September 24, 2025) - Lion One Metals Limited (TSXV: LIO) (OTCQX: LOMLF) ("Lion One" or the "Company") is pleased to announce that it has closed its previously announced and upsized non-brokered private placement for gross proceeds of $18,715,153 (the "LIFE Offering"). Pursuant to the LIFE Off ...

Core Viewpoint - Tier One Silver Inc. has successfully completed the second and final tranche of its upsized non-brokered private placement, raising a total of C$6,500,000, which reflects strong investor interest and confidence in the company and the precious metals market, particularly silver [1][2]. Group 1: Offering Details - The second tranche involved the issuance of 39,762,000 units at C$0.08 per unit, generating gross proceeds of C$3,180,960 [1]. - Each unit consists of one common share and one full common share purchase warrant, with the warrants allowing the purchase of shares at C$0.11 for up to 36 months [1]. - The total gross proceeds from the Offering are C$6,500,000, indicating robust demand and oversubscription [1][2]. Group 2: Use of Proceeds - The proceeds from the Offering will be utilized for exploration at the Curibaya project, investigation of new projects, and general working capital [2]. Group 3: Financial Advisory and Fees - The company paid cash finders' fees of C$165,256 and issued 2,065,700 non-transferable finders' warrants to Canadian registrants, along with additional fees to a European investment firm [2]. - A corporate finance fee was paid to 3L Capital Inc., which included $140,000 in cash, 1,250,000 units, and 1,750,000 warrants, all under the same terms as the Offering [2]. Group 4: Company Overview - Tier One Silver is focused on discovering world-class silver, gold, and copper deposits in South America, with its flagship project being Curibaya [5]. - The management and technical teams have a strong track record in capital raising and monetizing exploration success [5].

Group 1 - Stonegate Capital Partners has initiated coverage on Seabridge Gold Inc. (NYSE: SA) as of September 15, 2025 [1] - As of Q2 2025, Seabridge Gold reported cash and cash equivalents of $121.4 million, bolstered by a $100.2 million equity financing in February 2025 and a $30.5 million flow-through financing in June 2025 [1] - The company is focused on advancing its flagship KSM project and exploration at Iskut, 3 Aces, and Snowstorm [1] Group 2 - Seabridge Gold renewed its $750 million base shelf prospectus and $100 million ATM facility in early 2025 [1] - The company reported a Q2 net profit of $12.3 million ($0.12/share), a decrease from $45.2 million in Q2 2024, primarily due to the remeasurement of secured note liabilities [8] - Seabridge invested $21.1 million into projects during the quarter, and drilling at Iskut's Snip North confirmed a large copper-gold porphyry deposit, with a maiden resource estimate expected in early 2026 [8]

Swansea City AFC, the second tier football team, is seeking to raise £50 million in equity to accelerate the Welsh club’s growth https://t.co/HqfQ3uTpOM ...

Dryden Gold Corp. Announces the Closing Its of Previously Announced Upsized Equity Financing with Participation from Centerra Gold August 18, 2025 6:00 AM EDT | Source: Dryden Gold Corp. NOT FOR DISTRIBUTION TO US NEWS WIRE SERVICES OR FOR DISSEMINATON INTO THE USA Vancouver, British Columbia--(Newsfile Corp. - August 18, 2025) - Dryden Gold Corp. (TSXV: DRY) (OTCQB: DRYGF) (FSE: X7W) ("Dryden Gold" or the "Company is pleased to announce that it has closed (the "Closing") its previously announced (August 8, ...

Core Insights - TMX Group reported a significant decrease in financing activity on the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSXV) for July 2025, with total financings raised down 68% from the previous month but up 255% compared to July 2024 [2][4]. TSX Summary - In July 2025, TSX welcomed 12 new issuers, a decrease from 25 in June 2025 and an increase from 10 in July 2024 [2][5]. - Total financings raised amounted to $1.22 billion, a sharp decline from $3.77 billion in June 2025 but a significant increase from $343.36 million in July 2024 [5]. - The total number of financings was 27, down from 55 in the previous month and up from 17 in July 2024 [2][5]. - Year-to-date statistics show 152 new issuers listed, a 76.7% increase from 86 in 2024, and total financings raised of $9.71 billion, down 8% from $10.56 billion in 2024 [6]. TSXV Summary - TSXV had one new issuer in July 2025, down from five in June 2025 and three in July 2024 [4][7]. - Total financings raised were $705.31 million, a slight decrease of 3% from the previous month but up 49% from July 2024 [4][8]. - The total number of financings was 139, compared to 100 in June 2025 and 93 in July 2024 [4][8]. - Year-to-date statistics indicate 23 new issuers listed, a decrease of 20.7% from 29 in 2024, with total financings raised of $4.02 billion, a 63% increase from $2.46 billion in 2024 [9]. Market Capitalization - The market capitalization of listed issues on TSX was approximately $5.56 trillion in July 2025, reflecting growth from $4.63 trillion in July 2024 [5][6]. - TSXV's market capitalization was around $112.08 billion, up 42.2% from $78.83 billion in July 2024 [9].

Core Viewpoint - Assembly Biosciences, Inc. has announced a registered offering of common stock and warrants, aiming to raise capital for its innovative therapeutics targeting serious viral diseases [1][4]. Group 1: Offering Details - The offering consists of 5,591,840 shares of common stock and pre-funded warrants for 1,040,820 shares, with a combined price of $19.60 per share and accompanying warrants [1]. - Each pre-funded warrant has a nominal exercise price of $0.001 and is immediately exercisable, while Class A and Class B warrants have an exercise price of $21.60 and specific expiration conditions [1]. - The offering and a private placement with Gilead Sciences, Inc. are expected to close on August 11, 2025, contingent upon customary closing conditions [4]. Group 2: Investor Participation - The offering includes participation from both new and existing investors, such as Commodore Capital, Blackstone Multi-Asset Investing, and Farallon Capital Management [2]. - Gilead will purchase 2,295,920 shares in a private placement at the same price as the offering, which will not be registered under the Securities Act [3]. Group 3: Use of Proceeds - The net proceeds from the offering and private placement will be utilized for general corporate purposes [4]. Group 4: Company Overview - Assembly Biosciences is focused on developing small-molecule therapeutics aimed at serious viral diseases, including herpesvirus and hepatitis infections [7][8].